disease 1,782 words KG: ent-dise-420da99b
Contents

Behavioral Variant Frontotemporal Dementia (bvFTD)

Disease Info
Prevalence15-22 per 100,000 in the 45-65 age group; a 2025 meta-analysis reported a pooled estimate of 9.17 per 100,000[@connectomebased]
Incidence2.7-4.1 per 100,000 person-years
Age at onsetTypically 45-65 years (range 21-85); mean onset age approximately 58 years
SexMale predominance with a ratio of 1.3-1.6:1
Diagnostic delayAverage 3-6 years from symptom onset; approximately 50% receive an initial psychiatric diagnosis[^6]
Proportion of FTDApproximately 60% of all FTD cases
Familial proportionApproximately 40% have a positive family history
Salience networkCentered on the anterior cingulate cortex and frontoinsular cortex; its disruption explains disinhibition, impaired social cognition, and emotional blunting
Default mode networkReciprocal dysregulation with the salience network; paradoxically preserved or increased early in bvFTD
Reward and motivation circuitsVentromedial prefrontal and orbitofrontal cortex dysfunction explains apathy and dietary changes
Theory of mind networkMedial prefrontal and temporal pole disruption underlies loss of empathy
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (11)

Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
APOE-TREM2 Interaction Modulation
Score: 0.74
Cross-Seeding Prevention Strategy
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
TREM2-Dependent Microglial Senescence Transition
Score: 0.58
Lysosomal Membrane Repair Enhancement
Score: 0.54
Cryptic Exon Silencing Restoration
Score: 0.53
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47

Related Analyses (11)

RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived

Related Experiments (16)

FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.